Secunderabad Chronicle

Alpha-1 Antitrypsin Deficiency Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

 Breaking News
  • No posts were found

Alpha-1 Antitrypsin Deficiency Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

September 19
00:35 2023
Alpha-1 Antitrypsin Deficiency Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

DelveInsight’s, “Alpha1-Antitrypsin Deficiency Pipeline Insight 2023” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Alpha1-Antitrypsin Deficiency pipeline landscape. It covers the Alpha1-Antitrypsin Deficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Alpha1-Antitrypsin Deficiency Pipeline Report

  • DelveInsight’s Alpha-1 Antitrypsin Deficiency pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Alpha-1 Antitrypsin Deficiency treatment.
  • The leading companies working in the Alpha-1 Antitrypsin Deficiency Market include Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada, Ltd, and others.
  • Promising Alpha-1 Antitrypsin Deficiency Pipeline Therapies in the various stages of development include Fazirsiran Injection, Aerosolized, Recombinant Alpha 1-Antitrypsin, INBRX-101/rhAAT-Fc, Kamada-API, Kamada-AAT for Inhalation, 80mg, and others.
  • On August 2023, Grifols Therapeutics LLC announced a study of Phase 1 & 2 Clinical Trials for Alpha-1 15% and Liquid Alpha1-Proteinase Inhibitor (Human). The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 144 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in participants with Alpha1-Antitrypsin Deficiency (AATD).
  • On September 2023, Takeda announced a study of Phase 3 Clinical Trials for Fazirsiran Injection. The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics).

 

Request a sample and discover the recent advances in Alpha-1 Antitrypsin Deficiency Treatment Drugs @ Alpha-1 Antitrypsin Deficiency Pipeline Report

 

The Alpha-1 Antitrypsin Deficiency pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Alpha-1 Antitrypsin Deficiency drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Alpha-1 Antitrypsin Deficiency clinical trial landscape.

 

Alpha-1 Antitrypsin Deficiency Overview

Alpha-1-antitrypsin (AAT) is a protein produced in the liver that protects the body’s tissues from being damaged by infection-fighting agents released by its immune system. In alpha-1 antitrypsin deficiency, the body’s normal production of AAT is reduced, resulting in the destruction of sensitive lung tissue. AAT deficiency is inherited.

 

Find out more about Alpha-1 Antitrypsin Deficiency Treatment Drugs @ Drugs for Alpha-1 Antitrypsin Deficiency Treatment

 

Alpha-1 Antitrypsin Deficiency Emerging Drugs Profile

  • ARO AAT: Arrowhead Pharmaceuticals
  • ALN-AAT02: Alnylam Pharmaceuticals

 

Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics Assessment

There are approx. 12+ key companies which are developing the therapies for Alpha-1 Antitrypsin Deficiency. The Alpha-1 Antitrypsin Deficiency companies which have their Alpha-1 Antitrypsin Deficiency drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

 

Learn more about the emerging Alpha-1 Antitrypsin Deficiency Pipeline Therapies @ Alpha-1 Antitrypsin Deficiency Clinical Trials Assessment

 

Scope of the Alpha-1 Antitrypsin Deficiency Pipeline Report

  • Coverage- Global
  • Alpha-1 Antitrypsin Deficiency Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Alpha-1 Antitrypsin Deficiency Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Alpha-1 Antitrypsin Deficiency Companies- Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada, Ltd, and others.
  • Alpha-1 Antitrypsin Deficiency Pipeline Therapies- Fazirsiran Injection, Aerosolized, Recombinant Alpha 1-Antitrypsin, INBRX-101/rhAAT-Fc, Kamada-API, Kamada-AAT for Inhalation, 80mg, and others.

 

Dive deep into rich insights for new drugs for Alpha-1 Antitrypsin Deficiency Treatment, Visit @ Alpha-1 Antitrypsin Deficiency Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Alpha-1 Antitrypsin Deficiency: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Alpha-1 Antitrypsin Deficiency– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. ARO AAT: Arrowhead Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug Name: Company Name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ALN-AAT02: Alnylam Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Alpha-1 Antitrypsin Deficiency Key Companies
  21. Alpha-1 Antitrypsin Deficiency Key Products
  22. Alpha-1 Antitrypsin Deficiency- Unmet Needs
  23. Alpha-1 Antitrypsin Deficiency- Market Drivers and Barriers
  24. Alpha-1 Antitrypsin Deficiency- Future Perspectives and Conclusion
  25. Alpha-1 Antitrypsin Deficiency Analyst Views
  26. Alpha-1 Antitrypsin Deficiency Key Companies
  27. Appendix

 

For further information on the Alpha-1 Antitrypsin Deficiency Pipeline therapeutics, reach out to Alpha-1 Antitrypsin Deficiency Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

Related Articles